SecBot SecBot
8-K ·Filed Nov 12, 2026

SLN

Silence Therapeutics plc
NEUTRAL
Impact 5/10
Horizonmonths Processed4d 18h ago SEC0001193125-26-457060
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The acquisition by Merck KGaA is the primary catalyst; monitor for shareholder vote and regulatory approvals in Q1 2027. The Q3 results are largely backward-looking and overshadowed by the deal.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$19.80
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.15%
T+1 · $19.83
Vs SPY
+0.51%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $19.80entry
  2. T+1 · 4d ago +0.15%α +0.51% · $19.83
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Silence Therapeutics reported Q3 2026 net loss of $12.4 million ($0.08 per share), narrower than the $21.0 million loss ($0.15 per share) in Q3 2025, driven by lower R&D and G&A expenses. The filing is dominated by the pending acquisition by Merck KGaA, Darmstadt, Germany, announced on October 19, 2026, which is expected to close in Q1 2027.

Key Financial Metrics

EPS
−$0.08

Key Facts

  • Net loss of $12.4 million for Q3 2026, compared to $21.0 million in Q3 2025
  • Cash and cash equivalents were $247.7 million as of September 30, 2026, including $201.3 million from an upsized public offering in August 2026
  • R&D expenses decreased to $9.3 million from $20.5 million year-over-year
  • On October 19, 2026, Silence entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany
  • Transaction expected to close in Q1 2027, subject to customary conditions
  • Total outstanding shares were 186,609,073 as of September 30, 2026

Financial Impact

Net loss improved by $8.6 million year-over-year; cash position strengthened by $201.3 million from equity offering

net losscashR&D expensesG&A expenses

Risk Factors

  • Acquisition may not close due to regulatory or shareholder approval issues
  • Competing acquisition proposals could emerge
  • Litigation related to the transaction could cause delays or expenses

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-457060
Document: d101909d8k.htm0001193125-26-457060
Document: 0001193125-26-457060-index-headers.html0001193125-26-457060
Document: 0001193125-26-457060-index.html0001193125-26-457060
Document: 0001193125-26-457060.txt0001193125-26-457060
8-K Data (Synthetic)0001193125-26-457060

Track record

15 reports on SLN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
  2. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  3. Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Viewing Entry $19.80 Now $19.80 −0.00% settles Nov 19
  5. Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
  6. Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
  7. Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  9. Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
  10. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026